MiNK Therapeutics (NASDAQ:INKT) Posts Earnings Results, Beats Estimates By $0.16 EPS

MiNK Therapeutics (NASDAQ:INKT) announced its earnings results on Wednesday. The company reported ($0.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.16, Zacks reports.

Here are the key takeaways from MiNK Therapeutics’ conference call:

• MiNK has initiated a randomized Phase II ARDS trial enrolling 90 patients, comparing agenT-797 plus standard care with placebo plus standard care. The company says the protocol could transition seamlessly to Phase III, with preliminary data targeted for the second half of 2026; endpoints include survival and ventilator-free days.
• Management highlighted Phase II gastric cancer results in which median overall survival exceeded 23 months in an immune-primed cohort, with some patients still alive years after treatment. These are company-cited observations from a heavily pretreated population, and follow-up is ongoing.
• MiNK reported that the same agenT-797 product showed different immune activity in cancer and ARDS patient analyses, and said it is evaluating biomarkers that may help identify patients most likely to respond. The findings are early translational evidence, not proof of clinical benefit in the randomized trial.
• MiNK ended the first quarter with approximately $9.5 million in cash, after repaying about $5.2 million of debt and raising roughly $3 million through an at-the-market offering. Management expects at least 12 months of runway, including the ARDS trial, while the cash balance and ATM financing indicate continued funding needs may remain relevant.

MiNK Therapeutics Stock Up 3.9%

Shares of INKT traded up $0.39 during trading hours on Wednesday, hitting $10.40. 6,528 shares of the company were exchanged, compared to its average volume of 100,029. MiNK Therapeutics has a fifty-two week low of $8.48 and a fifty-two week high of $16.93. The company has a market cap of $53.04 million, a price-to-earnings ratio of -4.33 and a beta of 0.49. The firm’s fifty day moving average is $11.19 and its 200 day moving average is $11.24.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Zacks Research downgraded MiNK Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 12th. HC Wainwright assumed coverage on shares of MiNK Therapeutics in a research report on Wednesday, November 4th. They set a “buy” rating and a $38.00 price target on the stock. B. Riley Financial reiterated a “buy” rating and issued a $50.00 price objective (up from $43.00) on shares of MiNK Therapeutics in a research note on Wednesday, October 21st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of MiNK Therapeutics in a report on Friday, October 2nd. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $44.00.

Insider Buying and Selling

In related news, CEO Jennifer Buell sold 6,938 shares of the company’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $10.56, for a total transaction of $73,265.28. Following the completion of the sale, the chief executive officer owned 74,195 shares of the company’s stock, valued at $783,499.20. This represents a 8.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 20.40% of the stock is currently owned by company insiders.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell therapies for cancer. The company’s platform is based on invariant natural killer T (iNKT) cells, an immune-cell type that can recognize cancer-related targets and help stimulate broader anti-tumor immune responses. MiNK’s lead product candidate, agenT-797, is an allogeneic, or donor-derived, iNKT cell therapy designed to be developed as an off-the-shelf treatment. The candidate is being evaluated for use in oncology, including in combination with other cancer treatments such as immune checkpoint inhibitors.